Mass spectrometry

AG Tenzer

Core Facility Mass Spectrometry

Prof. Tenzer´s heads the "Core Facility for Mass Spectrometry" (CFMS) at the UMC, which was established in 2005 as part of the Forschungszentrum Immuntherapie (FZI). The laboratory is equipped with a Beckman Biomek i7 robotic sample preparation platform to enable reproducible high-throughput processing of biological samples, several latest generation LC-MS instrument platforms, including Bruker TIMS-TOF Pro 2 systems and FAIMS-equipped Thermo Exploris 480 platforms, which provide cutting edge sensitivity and proteome coverage. The group focuses on the development and application of methods for label-free quantitative proteomics using data-independent acquisition workflows in systems medicine, the development of benchmarking methods and software for quantitative proteomics. In addition, a dedicated data system comprised of several high performance multicore workstations for data processing and data analysis are available for data analysis.
Among other bioinformatic approaches, algorithmic tools developed in the group have been successfully implemented into the ISOQuant pipeline, which was the first free software to support the analysis of IMS-MSE (mass spectrometry / ion-mobility spectrometry–mass spectrometry) acquired on Waters instruments platforms and significantly improves data quality and reproducibility. In a collaborative project with the Cox group, we recently introduced MaxQuant DIA, which is capable of quantifying > 10.000 proteins from mixed proteome samples with high precision and accuracy on both TIMS-TOF and Orbitrap based LC-MS platforms using data-independent acquisition workflows.

AG Bindila

Clinical Lipidomics Group

The group of Dr. Laura Bindila focuses on absolute quantification and qualitative lipid profiling in various biospecimens under physiological and pathophysiological conditions – especially in the context of neurological, cardiovascular and infectious diseases. Additional goals of the group encompass direct translation of disease-associated lipid changes into quantitative biological assays to shed further light on underlying disease mechanisms, lipid marker discovery and monitoring, lipid drug target discovery and therapy monitoring. Dr. Laura Bindila heads the Lipidomics research group and the Clinical Lipidomics Core Facility at the Institute of Physiological Chemistry at the University Medical Center Mainz.
Targeted discovery as well as absolute quantification of selected lipids can be realized by LC/MS profiling. This approach is especially suitable for low abundant lipids. In the Clinical Lipidomics Core Facility high-end mass spectrometry platforms such as the timsTOF Pro 2 and QTRAP- MS are available for different analyses. To allow high-throughput measurements and to assure reproducible results, a semi-automated sample processing has been implemented. Dedicated software solutions as well as the necessary expertise for lipid identification and quantification are available.
Within the DIASyM Research Core Dr. Laura Bindila’s group will develop LC-IMSDIA-MS/MS methods to allow a deep phenotyping of plasma lipids. In a high-throughput setting plasma lipids will be extracted in a semiautomated fashion from human plasma samples of the MyoVasc and GHS studies. In combination with proteomic, metabolomic as well as other clinical data sets this will allow a multi-omics evaluation of heart failure patients. In close collaboration with the Knowledge Mining group headed by Prof. Miguel Andrade new software tools to describe and identify lipids in human plasma will be developed.